Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups

Cytogenetically-defined subgroups of acute myeloid leukaemia have distinct biologies, clinical features and outcomes. Evidence from therapy-related leukaemia suggests that chromosomal abnormalities are also markers of exposure. Our results suggest that the smoking-associated risk for acute myeloid l...

Descripción completa

Detalles Bibliográficos
Autores principales: Moorman, A V, Roman, E, Cartwright, R A, Morgan, G J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746540/
https://www.ncbi.nlm.nih.gov/pubmed/11857012
http://dx.doi.org/10.1038/sj.bjc.6600010
Descripción
Sumario:Cytogenetically-defined subgroups of acute myeloid leukaemia have distinct biologies, clinical features and outcomes. Evidence from therapy-related leukaemia suggests that chromosomal abnormalities are also markers of exposure. Our results suggest that the smoking-associated risk for acute myeloid leukaemia is restricted to the t(8;21)(q22;q22) subgroup. This supports the hypothesis that distinct cytogenetic subgroups of acute myeloid leukaemia have separate aetiologies. British Journal of Cancer (2002) 86, 60–62. DOI: 10.1038/sj/bjc/6600010 www.bjcancer.com © 2002 The Cancer Research Campaign

Ejemplares similares